NCT01605916View on ClinicalTrials.gov

Investigate the Safety and Tolerability of AZD6244 Monotherapy or + Docetaxel in Japanese Patients With Advanced Solid Malignancies or Non-Small Cell Lung Cancer

PHASE1CompletedINTERVENTIONAL
Enrollment

33

Participants

Timeline

Start Date

June 30, 2012

Primary Completion Date

April 30, 2015

Study Completion Date

May 31, 2015

Conditions
Neoplasms,Metastatic Cancer,Non-Small Cell Lung CancerAdvanced Solid Malignancies
Interventions
DRUG

AZD6244

Tablet Oral bid

Trial Locations (3)

Unknown

Research Site, Fukuoka

Research Site, Kashiwa-shi

Research Site, Nagoya

Sponsors

Lead Sponsor

AstraZeneca
All Listed Sponsors
lead

AstraZeneca

INDUSTRY

NCT01605916 - Investigate the Safety and Tolerability of AZD6244 Monotherapy or + Docetaxel in Japanese Patients With Advanced Solid Malignancies or Non-Small Cell Lung Cancer | Biotech Hunter | Biotech Hunter